US Stock MarketDetailed Quotes

ALXO ALX Oncology

Watchlist
  • 1.515
  • -0.115-7.06%
Close Jan 24 16:00 ET
  • 1.490
  • -0.025-1.65%
Post 20:01 ET
79.91MMarket Cap-0.51P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    72839823
    72839823
    Yesterday 01:09
    $ALX Oncology (ALXO.US)$ , Why Jeffries cut it’s rating saying it did not meet the expectation?  The report seems to be better than what Jeffries said.
    3
    Trytosaveabit
    Trytosaveabit
    Jan 23 07:07
    news
    $ALX Oncology (ALXO.US)$ ALX Oncology Presents Positive Updated Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients With HER2-Positive Gastric Cancer
    GlobeNewswire· 6 mins ago
    Jaguar8
    Jaguar8
    Jan 23 07:01
    NEWS
    $ALX Oncology (ALXO.US)$
    ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
    Thursday, 23rd January at 8:00 am
    • Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trial
    • Greatest ...
    Jaguar8
    Jaguar8
    Jan 21 16:10
    NEWS
    $ALX Oncology (ALXO.US)$
    ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
    Tuesday, 21st January at 5:00 pm
    • Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer
    SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ: ALXO), a clinical-stage ...
    Jaguar8
    Jaguar8
    Dec 10, 2024 08:02
    NEWS
    $ALX Oncology (ALXO.US)$
    ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
    Tuesday, 10th December at 9:00 am
    Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast cancer who had received multiple HER2-targeted agents, including fam-trastuzumab deruxt...
Read more
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Meta Platforms
META
+1.73%
Alphabet-C
GOOG
+1.16%
Alphabet-A
GOOGL
+1.13%
Vale SA
VALE
+1.01%
Coinbase
COIN
+0.67%

Unlock the Full List